N
FBRX icon

Nuveen’s Forte Biosciences FBRX Stock Holding History

Nuveen’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,614
Closed -$1.15M – 3331
2022
Q1 		$1.15M Hold
1,614
– – ﹤0.01% 2762
2021
Q4 		$1.15M Sell
1,614
-280
-15% -$18.8K ﹤0.01% 2810
2021
Q3 		$1.35M Buy
1,894
+144
+8% +$79.8K ﹤0.01% 2854
2021
Q2 		$1.47M Buy
+1,750
New +$1.58M ﹤0.01% 2844
2020
Q2 		– Sell
-110
Closed -$50K – 3303
2020
Q1 		$50K Buy
+110
New +$43K ﹤0.01% 3105
2019
Q4 		– Sell
-323
Closed -$80K – 3251
2019
Q3 		$80K Buy
323
+65
+25% +$98.7K ﹤0.01% 3179
2019
Q2 		$646K Buy
+258
New +$765K ﹤0.01% 2918

Other funds holding FBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen's FBRX Position: Q2 2022 in Review

Nuveen sold out of Forte Biosciences (FBRX) in Q2 2022, closing a stake of 1,614 shares — an estimated $1.15M sold.

Nuveen first reported a position in FBRX in Q2 2019 and held it in 7 quarters. The position peaked at $1.47M in Q2 2021. 39 funds tracked by Wall St. Rank hold FBRX as of Q2 2022.

  • Nuveen reported no remaining Forte Biosciences position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 1,614 Forte Biosciences shares in Q2 2022, an estimated $1.15M.
  • Nuveen first reported a position in Forte Biosciences in Q2 2019 and held it in 7 quarters.
  • Nuveen's Forte Biosciences position peaked at $1.47M in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.